NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.
NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 12, 2009 | Series Unknown | $54.80M | 3 | — | — | Detail |
Jun 1, 2006 | Series B | $46M | 1 | — | — | Detail |
May 1, 2000 | Series A | $14M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
LODH Immunology Fund | — | Series Unknown |
Ingro Finanz AG | — | Series Unknown |
Varuma | — | Series Unknown |